<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04415047</url>
  </required_header>
  <id_info>
    <org_study_id>P02C320</org_study_id>
    <nct_id>NCT04415047</nct_id>
  </id_info>
  <brief_title>THE ALIGN-AR PIVOTAL TRIAL: JenaValve Pericardial TAVR Aortic Regurgitation Study</brief_title>
  <acronym>ALIGN-AR</acronym>
  <official_title>A Study to Assess Safety and Effectiveness of the JenaValve Trilogy™ Heart Valve System in the Treatment of High Surgical Risk Patients With Symptomatic, Severe Aortic Regurgitation (AR)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>JenaValve Technology, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>JenaValve Technology, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To collect information about treatment for symptomatic severe Aortic Regurgitation (AR),&#xD;
      which affects the aortic valve in the heart. Aortic regurgitation is a condition where aortic&#xD;
      valve in the heart does not close tightly and allows some blood to leak back into the heart&#xD;
      chamber. Symptoms of aortic regurgitation may include fatigue and shortness of breath. The&#xD;
      preferred treatment for severe aortic regurgitation is aortic valve replacement surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will examine the use of TAVR (Transcatheter Aortic Valve Replacement), which is a&#xD;
      minimally invasive procedure designed to replace the aortic valve inside the heart. In this&#xD;
      study, TAVR will be performed using the JenaValve Pericardial TAVR System, which is intended&#xD;
      to help treat symptomatic severe aortic regurgitation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 22, 2020</start_date>
  <completion_date type="Anticipated">June 2027</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>All-Cause Mortality at 1 Year</measure>
    <time_frame>1 year</time_frame>
    <description>All-cause mortality within the first 12 months post index procedure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>All Stroke</measure>
    <time_frame>30 days</time_frame>
    <description>Number of patients that had a stroke</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Major Bleeding</measure>
    <time_frame>30 days</time_frame>
    <description>Number of patients that had any of these events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Acute Kidney Injury</measure>
    <time_frame>30 days</time_frame>
    <description>Number of patients that had these events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Major Vascular Complications</measure>
    <time_frame>30 days</time_frame>
    <description>Number of patients that had these events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Surgery/intervention related to the device</measure>
    <time_frame>30 days</time_frame>
    <description>Number of patients that had these events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Permanent pacemaker implantation</measure>
    <time_frame>30 days</time_frame>
    <description>Number of patients that had these events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total aortic regurgitation</measure>
    <time_frame>30 days</time_frame>
    <description>Number of patients that had these events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>KCCQ</measure>
    <time_frame>1 year</time_frame>
    <description>KCCQ Improvement</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Aortic Regurgitation</condition>
  <condition>Aortic Valve Insufficiency</condition>
  <condition>Aortic Insufficiency</condition>
  <condition>Aortic Valve Disease</condition>
  <arm_group>
    <arm_group_label>Transcatheter Aortic Valve Replacement (TAVR)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAVR with JenaValve Pericardial Valve and Delivery System Intervention Device: JenaValve Pericardial TAVR System</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>JenaValve Pericardial TAVR System</intervention_name>
    <description>TAVR with JenaValve Pericardial Valve and Delivery System</description>
    <arm_group_label>Transcatheter Aortic Valve Replacement (TAVR)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient with severe aortic regurgitation (AR).&#xD;
&#xD;
          -  Patient at high risk for open surgical valve replacement&#xD;
&#xD;
          -  Patient symptomatic according to NYHA functional class II or higher&#xD;
&#xD;
          -  The study patient has been informed of the nature of the study, agrees to its&#xD;
             provisions and has provided written informed consent as approved by the Institutional&#xD;
             Review Board (IRB)/ Ethics Committee (EC) of the respective clinical site.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Congenital uni or bicuspid aortic valve morphology&#xD;
&#xD;
          -  Previous prosthetic aortic valve (bioprosthesis or mechanical) implant&#xD;
&#xD;
          -  Endocarditis or other active infection&#xD;
&#xD;
          -  Need for urgent or emergent TAVR procedure for any reason&#xD;
&#xD;
          -  Cardiogenic shock or hemodynamic instability requiring inotropic support or&#xD;
             ventricular assist device&#xD;
&#xD;
          -  Severe mitral regurgitation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin B. Leon, MD</last_name>
    <role>Study Chair</role>
    <affiliation>New York-Presbyterian/ Columbia University Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Torsten P. Vahl, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>New York-Presbyterian/ Columbia University Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Vinod H. Thourani, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Piedmont Healthcare</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stephan Baldus, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Herzzentrum der Universität zu Köln</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Vinny Podichetty, Vice President: Clinical &amp; Med Affairs</last_name>
    <phone>949-396-7510</phone>
    <email>podichetty@jenavalve.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cedars Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Khaled Alsabaawi</last_name>
      <phone>310-423-6226</phone>
      <email>Khaled.Alsabaawi@cshs.org</email>
    </contact>
    <investigator>
      <last_name>Raj Makkar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>California Pacific Medical Center Research Institute</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Milena Ferreira</last_name>
      <phone>415-600-5707</phone>
      <email>ferreiml@sutterhealth.org</email>
    </contact>
    <investigator>
      <last_name>David V. Daniels, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MedStar Washington Hospital Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erin Collins</last_name>
      <phone>202-877-6622</phone>
      <email>Erin.C.Collins@medstar.net</email>
    </contact>
    <investigator>
      <last_name>Ron Waksman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Piedmont Healthcare</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30309</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Akimi Rhodes</last_name>
      <phone>404-605-2371</phone>
      <email>akimi.rhodes@piedmont.org</email>
    </contact>
    <investigator>
      <last_name>Vivek Rajagopal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Charles</last_name>
      <phone>404-686-1249</phone>
      <email>elizabeth.z.charles@emory.edu</email>
    </contact>
    <investigator>
      <last_name>Adam B. Greenbaum, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wendy Warshal</last_name>
      <phone>734-232-2703</phone>
      <email>warshal@med.umich.edu</email>
    </contact>
    <investigator>
      <last_name>Stanley J. Chetcuti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Morristown Medical Center</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>07960</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tracy Oster</last_name>
      <phone>973-971-5951</phone>
      <email>Tracy.Oster@atlantichealth.org</email>
    </contact>
    <investigator>
      <last_name>Philippe Généreux, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rutgers Robert Wood Johnson Medical School/ Rutgers Robert Wood University Hospital</name>
      <address>
        <city>Piscataway</city>
        <state>New Jersey</state>
        <zip>08901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susette Coyle</last_name>
      <phone>732-235-8142</phone>
      <email>coylesu@rwjms.rutgers.edu</email>
    </contact>
    <investigator>
      <last_name>Mark J. Russo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New York-Presbyterian/ Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Borden</last_name>
      <phone>212-342-5129</phone>
      <email>sb1097@cumc.columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Susheel Kodali, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Christ Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ellen Anderson</last_name>
      <phone>513-585-0537</phone>
      <email>ellenanderson@thechristhospital.com</email>
    </contact>
    <investigator>
      <last_name>Dean Kereiakes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohio Health Research Institute</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43214</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katy Monnin</last_name>
      <phone>614-566-5768</phone>
      <email>Katy.Monnin@ohiohealth.com</email>
    </contact>
    <investigator>
      <last_name>Steven J Yakubov, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>LilyAna Folk</last_name>
      <phone>503-494-3925</phone>
      <email>folkl@ohsu.edu</email>
    </contact>
    <investigator>
      <last_name>Firas Zahr, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor Scott &amp; White Research Institute</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Simona Marin</last_name>
      <phone>469-814-4818</phone>
      <email>simona.marin@bswhealth.org</email>
    </contact>
    <investigator>
      <last_name>Molly Szerlip, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Houston Methodist</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lashawna Green</last_name>
      <phone>713-441-5200</phone>
      <email>lagreen2@houstonmethodist.org</email>
    </contact>
    <investigator>
      <last_name>Michael Reardon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Tushinski</last_name>
      <phone>206-685-4346</phone>
      <email>jtushin@cardiology.washington.edu</email>
    </contact>
    <investigator>
      <last_name>James McCabe, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Zoghbi WA, Adams D, Bonow RO, Enriquez-Sarano M, Foster E, Grayburn PA, Hahn RT, Han Y, Hung J, Lang RM, Little SH, Shah DJ, Shernan S, Thavendiranathan P, Thomas JD, Weissman NJ. Recommendations for Noninvasive Evaluation of Native Valvular Regurgitation: A Report from the American Society of Echocardiography Developed in Collaboration with the Society for Cardiovascular Magnetic Resonance. J Am Soc Echocardiogr. 2017 Apr;30(4):303-371. doi: 10.1016/j.echo.2017.01.007. Epub 2017 Mar 14. Review.</citation>
    <PMID>28314623</PMID>
  </reference>
  <reference>
    <citation>Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP 3rd, Fleisher LA, Jneid H, Mack MJ, McLeod CJ, O'Gara PT, Rigolin VH, Sundt TM 3rd, Thompson A. 2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2017 Jun 20;135(25):e1159-e1195. doi: 10.1161/CIR.0000000000000503. Epub 2017 Mar 15. Review.</citation>
    <PMID>28298458</PMID>
  </reference>
  <reference>
    <citation>Iung B, Baron G, Butchart EG, Delahaye F, Gohlke-Bärwolf C, Levang OW, Tornos P, Vanoverschelde JL, Vermeer F, Boersma E, Ravaud P, Vahanian A. A prospective survey of patients with valvular heart disease in Europe: The Euro Heart Survey on Valvular Heart Disease. Eur Heart J. 2003 Jul;24(13):1231-43.</citation>
    <PMID>12831818</PMID>
  </reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>May 31, 2020</study_first_submitted>
  <study_first_submitted_qc>May 31, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 4, 2020</study_first_posted>
  <last_update_submitted>August 20, 2021</last_update_submitted>
  <last_update_submitted_qc>August 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Valvular Heart Disease</keyword>
  <keyword>Aortic Incompetence</keyword>
  <keyword>Aortic Valve Incompetence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Disease</mesh_term>
    <mesh_term>Aortic Valve Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

